Compare M&T Bank Corporation (MTB) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? M&T Bank Corporation trades at $215.86 (market cap $31.47B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: M&T Bank Corporation is far larger — about 4.2× Spyre Therapeutics Inc. Common Stock's market cap, and M&T Bank Corporation pays a 2.75% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold M&T Bank Corporation for 99 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MTB | SYRE | |
|---|---|---|
Market Cap | $31.47B | $7.52B |
Volume | 743,357 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $254.09 | $108.92 |
52-Week Low | $178.63 | $22.18 |
Typical Hold Time | 99 Days | 0 Days |
Enterprise Value | $47.83B | $6.52B |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank Corporation (MTB) trades at $216.05, down 1.75% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026), a P/E of 11.54, and net income margin of 30.85%. Recent developments include a new Connecticut branch opening and AI investments to drive loan growth. Cash flow trends show operational strength despite negative net cash flow in 2025.
MTB presents a value opportunity with attractive valuation metrics and dividend stability, though technical weakness and competitive banking pressures pose near-term risks. Analyst consensus targets $258.92 (19.8% upside) with 31% buy ratings, but investors should monitor loan growth execution and interest rate sensitivity.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
